{
    "Clinical Trial ID": "NCT00321464",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid",
        "  Zoledronic acid 4 mg by intravenous injection with subcutaneous denosumab placebo once every 4 weeks",
        "INTERVENTION 2: ",
        "  Denosumab",
        "  Denomsumab 120 mg subcutaneously with intravenous zoledronic acid placebo once every 4 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adults with histologically or cytologically confirmed breast adenocarcinoma",
        "  radiographic evidence of at least one bone mets",
        "  Easter Cooperative Oncology Group status of 0, 1 or 2;",
        "  adequate organ function",
        "Exclusion Criteria:",
        "  Current or prior IV bisphosphonate administration",
        "  current or prior oral bisphosphonates for bone mets",
        "  life expectancy of less than 6 months"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)",
        "  Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.",
        "  Time frame: Up to 34 months",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid",
        "  Arm/Group Description: Zoledronic acid 4 mg by intravenous injection with subcutaneous denosumab placebo once every 4 weeks",
        "  Overall Number of Participants Analyzed: 1020",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  372",
        "Results 2: ",
        "  Arm/Group Title: Denosumab",
        "  Arm/Group Description: Denomsumab 120 mg subcutaneously with intravenous zoledronic acid placebo once every 4 weeks",
        "  Overall Number of Participants Analyzed: 1026",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  315"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 471/1013 (46.50%)",
        "  Anaemia 32/1013 (3.16%)",
        "  Bone marrow failure 0/1013 (0.00%)",
        "  Coagulopathy 0/1013 (0.00%)",
        "  Disseminated intravascular coagulation 2/1013 (0.20%)",
        "  Febrile neutropenia 22/1013 (2.17%)",
        "  Haemolytic anaemia 1/1013 (0.10%)",
        "  Heparin-induced thrombocytopenia 1/1013 (0.10%)",
        "  Leukopenia 6/1013 (0.59%)",
        "  Lymphadenitis 0/1013 (0.00%)",
        "  Lymphadenopathy 1/1013 (0.10%)",
        "Adverse Events 2:",
        "  Total: 453/1020 (44.41%)",
        "  Anaemia 27/1020 (2.65%)",
        "  Bone marrow failure 1/1020 (0.10%)",
        "  Coagulopathy 4/1020 (0.39%)",
        "  Disseminated intravascular coagulation 0/1020 (0.00%)",
        "  Febrile neutropenia 17/1020 (1.67%)",
        "  Haemolytic anaemia 0/1020 (0.00%)",
        "  Heparin-induced thrombocytopenia 0/1020 (0.00%)",
        "  Leukopenia 6/1020 (0.59%)",
        "  Lymphadenitis 1/1020 (0.10%)",
        "  Lymphadenopathy 0/1020 (0.00%)"
    ]
}